Click Here for 5% Off Your First Aladdin Purchase!

Flunarizine - 98%, high purity , CAS No.52468-60-7, Channel blocker of Ca v3.1;Channel blocker of Ca v3.2;Channel blocker of Ca v3.3;Antagonist of D 2 receptor

  • Moligand™
  • ≥98%
Item Number
F610353
Grouped product items
SKUSizeAvailabilityPrice Qty
F610353-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,334.90
F610353-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,001.90
F610353-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$19.90
F610353-250mg
250mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$31.90
F610353-1g
1g
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$71.90
F610353-5g
5g
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$285.90

Basic Description

Synonymsflunarizine|Sibelium|52468-60-7|1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine|Flunarizinum|Flunarizina|Flunarizinum [INN-Latin]|Flunarizina [INN-Spanish]|Narzine|40218-96-0|UNII-R7PLA2DM0J|R7PLA2DM0J|(Z)-Flunarizine|EINECS 257-937-5|(E)-1-(Bis(4-fluo
Specifications & PurityMoligand™, ≥98%
Storage TempStore at 2-8°C,Argon charged
Shipped InWet ice
GradeMoligand™
Action TypeANTAGONIST, CHANNEL BLOCKER
Mechanism of actionChannel blocker of Ca v3.1;Channel blocker of Ca v3.2;Channel blocker of Ca v3.3;Antagonist of D 2 receptor
Product Description

Flunarizine is a potent dual Na+/Ca2+ channel (T-type) blocker. Flunarizine is a D2 dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects。


Names and Identifiers

IUPAC Name 1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine
INCHI InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+
InChi Key SMANXXCATUTDDT-QPJJXVBHSA-N
Canonical SMILES C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
Isomeric SMILES C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
Alternate CAS 52468-60-7,40218-96-0,30484-77-6 (di-hydrochloride)
PubChem CID 941361
MeSH Entry Terms Dihydrochloride, Flunarizine;Flunarizin;Flunarizine;Flunarizine Dihydrochloride;Flunarizine Hydrochloride;Hydrochloride, Flunarizine;R 14950;R-14950;R14950;Sibelium
Molecular Weight 404.5

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Teive HA, Troiano AR, Germiniani FM, Werneck LC.  (2004)  Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis..  Parkinsonism Relat Disord,  10  (4): (243-5).  [PMID:15120099]
2. Shen Y, Qi X, Wan T.  (2020)  The Treatment of Vestibular Migraine: A Narrative Review..  Ann Indian Acad Neurol,  23  (5): (602-607).  [PMID:33623258]
3. Olesen J.  (1986)  Role of calcium entry blockers in the prophylaxis of migraine..  Eur Neurol,  25 Suppl 1  (3): (72-9).  [PMID:3530775]
4. Capellà D, Laporte JR, Castel JM, Tristán C, Cos A, Morales-Olivas FJ.  (1988)  Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine..  BMJ,  297  (6650): (722-3).  [PMID:3147743]
5. von Brevern M, Lempert T.  (2020)  Vestibular Migraine: Treatment and Prognosis..  Semin Neurol,  40  (1): (83-86).  [PMID:31887753]
6. Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS.  (1984)  Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use..  Drugs,  27  (1): (6-44).  [PMID:6141044]
7. Amery WK.  (1983)  Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine..  Headache,  23  (2): (70-4).  [PMID:6343298]
8. Kariya S, Isozaki S, Masubuchi Y, Suzuki T, Narimatsu S.  (1995)  Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine..  Biochem Pharmacol,  50  (10): (1645-50).  [PMID:7503767]

Solution Calculators